Companies

Lilly

Lilly was founded in 1876 by Colonel Eli Lilly, a man driven by the vision of developing high-quality medicines for those who needed them most. More than 145 years later, we remain true to that vision—dedicated to the people who rely on our medicines, the healthcare professionals who prescribe them, our employees, and the communities we serve.

Our pipeline for neurodegenerative diseases is considered one of the most robust ones in the industry, built on nearly three decades of research and development. Right now, our focus is on developing therapies that could slow the progression of Alzheimer’s disease.

But we’re not stopping there. We’re also exploring new ways to treat symptoms of other forms of dementia. We’re honored to collaborate with leading researchers and institutions in the scientific community to advance research in neurodegenerative disorders.

We appreciate your interest in Eli Lilly (Suisse) SA and are happy to answer any questions you may have:

lilly_ch@lilly.com

Neurolite

Specializing in Neurodiagnostics and Non-Invasive Brain Stimulation (NIBS),

Neurolite is the exclusive distributor in Switzerland for brands like Natus (EMG- & PSG-systems), EBNeuro (EEG), Artinis (NIRS), BEL (HD-EEG), MagVenture (TMS), Neuroelectrics (portable EEG and tCS), Storz Medical (TPS)… providing cutting-edge technology to investigate and treat various clinical conditions.

NIBS-techniques are already routinely used in neurorehabilitation, pain medicine, psychiatry, both in research and clinics and are currently emerging as a powerful means to tackle neurodegenerative disorders such as Parkinson’s or Alzheimer’s disease.

Neurolite is looking for collaborations to advance clinical application of NIBS-methods in this field. Please contact us at

info@neurolite.ch for any request or information.

Carthera

Founded in 2010,

Carthera® is headquartered in Lyon. Carthera works closely with renowned academic institutions, like INSERM, Sorbonne University, AP-HP, the interdisciplinary Center for Neuroscience Frankfurt (ICNF), the VHIO Barcelona, Northwestern University and UCSF.

Carthera® is a clinical-stage company with its

SonoCloud® implant that temporarily opens the blood-brain barrier (BBB). SonoCloud® is presently being investigated in several

clinical trials in oncology as well as in neurodegenerative diseases.

Carthera is seeking active academic and industrial collaborations to explore the potential of its approach to neurodegenerative diseases. Feel free to get in touch with the Director of Preclinical Research,

Pierre De Rossi, to discuss your project and how Carthera can be of interest.

Contact:

pierre.derossi@carthera.eu

Support our mission

• Promote an interdisciplinary community: Engage with experts across various disciplines.
• Raise awareness: Contribute to greater awareness of neurodegenerative diseases.
• Position Switzerland as a Hub: Help establish Switzerland as a central player in neurodegenerative research, attracting young talents and leading researchers.

Your benefits

• Enhanced visibility: Showcase your company with logos and descriptions featured on our platform, reaching a diverse network of scientists, clinicians and key stakeholders.
• Exclusive sponsorship discounts: Profit from discounted rates for conference sponsorship opportunities.
• News sharing: Company news pertinent to the community will be shared on social media channels and the platform.Stay Informed: Receive the latest updates from the community and the field.